Drug Trial Radar · NCT01863550
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,087
Actual
Start
Dec 6, 2013
Primary completion
Dec 31, 2026
Study completion Feb 5, 2034
Sponsor
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 29, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bortezomib, lenalidomide, and dexamethasone are more or less effective than carfilzomib, lenalidomide, and dexamethasone in treating patients with multiple myeloma
Conditions
- Plasma Cell Myeloma
Interventions
BortezomibDrug
Given SC or IV
CarfilzomibDrug
Given IV
DexamethasoneDrug
Given PO
Laboratory Biomarker AnalysisOther
Optional correlative studies
LenalidomideDrug
Given PO
Quality-of-Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS) for the maintenance analysisTime frame: From the maintenance randomization to death due to any cause or, censored at the date last known alive, assessed up to 15 years
- Progression-free survival for the induction analysisTime frame: From the induction randomization until the earlier of progression or death due to any cause, assessed up to 15 years
Locations
920 sites in 2 countries. Site status is shown where the registry gives one.
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Mayo Clinic in Arizona
Scottsdale, Arizona
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
Veteran's Administration Medical Center
Little Rock, Arkansas
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills-Peninsula Medical Center
Burlingame, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Eden Hospital Medical Center
Castro Valley, California
UC Irvine Health Cancer Center-Newport
Costa Mesa, California
Sutter Davis Hospital
Davis, California
Kaiser Permanente-Fremont
Fremont, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Kaiser Permanente-Fresno
Fresno, California
Saint Jude Medical Center
Fullerton, California
Fremont - Rideout Cancer Center
Marysville, California
Memorial Medical Center
Modesto, California
Kaiser Permanente-Modesto
Modesto, California
Palo Alto Medical Foundation-Camino Division
Mountain View, California
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California
Sutter Cancer Research Consortium
Novato, California
Kaiser Permanente-Oakland
Oakland, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Eisenhower Medical Center
Rancho Mirage, California
Kaiser Permanente-Redwood City
Redwood City, California
Kaiser Permanente-Richmond
Richmond, California
Kaiser Permanente-Roseville
Roseville, California
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California
Sutter Roseville Medical Center
Roseville, California
Showing 40 of 920 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.